Sign In
Buy PCRX
$22.25
-0.710 (-3.09%)
At Close: Jun 02, 2026
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
04:01pm, Tuesday, 12'th May 2026
Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLU
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 08'th May 2026
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patie
Pacira BioSciences Mails Letter to Stockholders
04:20pm, Tuesday, 05'th May 2026
Details Success of Pacira's 5x30 Strategy and Solid First Quarter 2026 Results Reiterates Board's Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira's Highly Qualified
PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada
05:00pm, Friday, 01'st May 2026
SASKATOON, Saskatchewan, May 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform for pharma
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
02:26pm, Friday, 01'st May 2026
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release
08:17am, Friday, 01'st May 2026
Pacira BioSciences, a leader in non-opioid pain management, reported a notable insider sale amid ongoing option exercise activity.
Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
11:51pm, Thursday, 30'th Apr 2026
Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
Pacira (PCRX) Q1 Earnings Miss Estimates
07:26pm, Thursday, 30'th Apr 2026
Pacira (PCRX) came out with quarterly earnings of $0.6 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.62 per share a year ago.
Pacira BioSciences Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 30'th Apr 2026
-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed en
PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update
11:04am, Thursday, 30'th Apr 2026
SASKATOON, Saskatchewan, April 30, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharm
PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results
08:51pm, Wednesday, 29'th Apr 2026
SASKATOON, Saskatchewan, April 29, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for phar
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
04:20pm, Tuesday, 28'th Apr 2026
Urges Stockholders to Vote “FOR” Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- -- Findings show significant reductions in opioid consumption, healthcare res
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
08:00am, Thursday, 16'th Apr 2026
BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li
-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with l
